{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:03:44Z","timestamp":1792854224106,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41434-024-00488-4","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T13:01:47Z","timestamp":1726923707000},"page":"594-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K\/AKT pathway and represents a therapeutic target"],"prefix":"10.1038","volume":"31","author":[{"given":"Jing","family":"Qiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Qing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5235-6154","authenticated-orcid":false,"given":"Yi-Jun","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03635-w","volume":"20","author":"C Zhao","year":"2022","unstructured":"Zhao C, Yang ZY, Zhang J, Li O, Liu SL, Cai C, et al. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53\/mTOR pathway. J Transl Med. 2022;20:434.","journal-title":"J Transl Med"},{"key":"488_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/cco.2019.08.13","volume":"8","author":"MA Schmidt","year":"2019","unstructured":"Schmidt MA, Marcano-Bonilla L, Roberts LR. Gallbladder cancer: epidemiology and genetic risk associations. Chin Clin Oncol. 2019;8:31.","journal-title":"Chin Clin Oncol"},{"key":"488_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872\u20136.","journal-title":"Nat Genet"},{"key":"488_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/cco.2019.07.05","volume":"8","author":"AA Azizi","year":"2019","unstructured":"Azizi AA, Lamarca A, Valle JW. Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chin Clin Oncol. 2019;8:43.","journal-title":"Chin Clin Oncol"},{"key":"488_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","volume":"5","author":"X Song","year":"2020","unstructured":"Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020;5:230.","journal-title":"Signal Transduct Target Ther"},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.21037\/cco.2019.08.14","volume":"8","author":"M Javle","year":"2019","unstructured":"Javle M, Zhao H, Abou-Alfa GK. Systemic therapy for gallbladder cancer. Chin Clin Oncol. 2019;8:44.","journal-title":"Chin Clin Oncol"},{"key":"488_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati B, Lorenzini E, Ciarrocchi A. BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17:164.","journal-title":"Mol Cancer"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1021\/acsmedchemlett.2c00316","volume":"13","author":"RB Kargbo","year":"2022","unstructured":"Kargbo RB. Application of Selective SMARCA2\/4 PROTAC for Mutant Cancer Therapy. ACS Med Chem Lett. 2022;13:1209\u201310.","journal-title":"ACS Med Chem Lett"},{"key":"488_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41416-020-01079-x","volume":"123","author":"MM Mita","year":"2020","unstructured":"Mita MM, Mita AC. Bromodomain inhibitors a decade later: a promise unfulfilled? Br J Cancer. 2020;123:1713\u20134.","journal-title":"Br J Cancer"},{"key":"488_CR10","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1021\/acs.jmedchem.5b01865","volume":"59","author":"LJ Martin","year":"2016","unstructured":"Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016;59:4462\u201375.","journal-title":"J Med Chem"},{"key":"488_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45:592\u2013601.","journal-title":"Nat Genet"},{"key":"488_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.tig.2014.05.001","volume":"30","author":"AF Hohmann","year":"2014","unstructured":"Hohmann AF, Vakoc CR. A rationale to target the SWI\/SNF complex for cancer therapy. Trends Genet. 2014;30:356\u201363.","journal-title":"Trends Genet"},{"key":"488_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00704-7","volume":"12","author":"E Weisberg","year":"2022","unstructured":"Weisberg E, Chowdhury B, Meng C, Case AE, Ni W, Garg S, et al. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022;12:110.","journal-title":"Blood Cancer J"},{"key":"488_CR14","doi-asserted-by":"crossref","unstructured":"Mason LD, Chava S, Reddi KK, Gupta R. The BRD9\/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis. Cancers. 2021;13:5516.","DOI":"10.3390\/cancers13215516"},{"key":"488_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1570-9","volume":"10","author":"N Del Gaudio","year":"2019","unstructured":"Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Migliaccio A, Vermeulen M, et al. BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. Cell Death Dis. 2019;10:338.","journal-title":"Cell Death Dis"},{"key":"488_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.7150\/ijbs.57623","volume":"17","author":"FN Li","year":"2021","unstructured":"Li FN, Zhang QY, Li O, Liu SL, Yang ZY, Pan LJ, et al. ESRRA promotes gastric cancer development by regulating the CDC25C\/CDK1\/CyclinB1 pathway via DSN1. Int J Biol Sci. 2021;17:1909\u201324.","journal-title":"Int J Biol Sci"},{"key":"488_CR17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/cam4.4954","volume":"12","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, Gu X, Wei W, Wu Z, Gong F, Dong X. BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma. Cancer Med. 2023;12:1572\u201387.","journal-title":"Cancer Med"},{"key":"488_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09672-2","volume":"10","author":"Q Wu","year":"2019","unstructured":"Wu Q, Heidenreich D, Zhou S, Ackloo S, Kr\u00e4mer A, Nakka K, et al. A chemical toolbox for the study of bromodomains and epigenetic signaling. Nat Commun. 2019;10:1915.","journal-title":"Nat Commun"},{"key":"488_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrd.2016.256","volume":"16","author":"SX Pfister","year":"2017","unstructured":"Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16:241\u201363.","journal-title":"Nat Rev Drug Discov"},{"key":"488_CR20","doi-asserted-by":"crossref","unstructured":"Ahmed NS, Gatchalian J, Ho J, Burns MJ, Hah N, Wei Z, et al. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4. Proc Natl Acad Sci USA. 2022;119:e2110812119.","DOI":"10.1073\/pnas.2110812119"},{"key":"488_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u201373.","journal-title":"Nature"},{"key":"488_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119\u201323.","journal-title":"Nature"},{"key":"488_CR23","doi-asserted-by":"crossref","unstructured":"Xu Y, Vakoc CR. Targeting Cancer Cells with BET Bromodomain Inhibitors. Cold Spring Harb Perspect Med. 2017;7:a026674.","DOI":"10.1101\/cshperspect.a026674"},{"key":"488_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/cbic.201600184","volume":"17","author":"N Wang","year":"2016","unstructured":"Wang N, Li F, Bao H, Li J, Wu J, Ruan K. NMR Fragment Screening Hit Induces Plasticity of BRD7\/9 Bromodomains. Chembiochem. 2016;17:1456\u201363.","journal-title":"Chembiochem"},{"key":"488_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1021\/acs.jmedchem.5b00256","volume":"59","author":"NH Theodoulou","year":"2016","unstructured":"Theodoulou NH, Bamborough P, Bannister AJ, Becher I, Bit RA, Che KH, et al. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. J Med Chem. 2016;59:1425\u201339.","journal-title":"J Med Chem"},{"key":"488_CR26","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.21037\/tcr-21-42","volume":"10","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yao Q, Li H, Chen J. Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells. Transl Cancer Res. 2021;10:3364\u201372.","journal-title":"Transl Cancer Res"},{"key":"488_CR27","first-page":"781","volume":"53","author":"J Jiang","year":"2018","unstructured":"Jiang J, Liu HL, Tao L, Lin XY, Yang YD, Tan SW, et al. Let\u20117d inhibits colorectal cancer cell proliferation through the CST1\/p65 pathway. Int J Oncol. 2018;53:781\u201390.","journal-title":"Int J Oncol"},{"key":"488_CR28","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.2147\/OTT.S194332","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu Y, Yao J. Research progress of cystatin SN in cancer. Onco Targets Ther. 2019;12:3411\u20139.","journal-title":"Onco Targets Ther"},{"key":"488_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/kjm2.12619","volume":"39","author":"HB Liu","year":"2023","unstructured":"Liu HB, Bai J, Wang WX. CST1 promotes the proliferation and migration of PDGF-BB-treated airway smooth muscle cells via the PI3K\/AKT signaling pathway. Kaohsiung J Med Sci. 2023;39:145\u201353.","journal-title":"Kaohsiung J Med Sci"},{"key":"488_CR30","doi-asserted-by":"publisher","first-page":"11359","DOI":"10.2147\/OTT.S234328","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu Y, Ma H, Wang Y, Du X, Yao J. Cystatin SN Affects Cell Proliferation by Regulating the ER\u03b1\/PI3K\/AKT\/ER\u03b1 Loopback Pathway in Breast Cancer. Onco Targets Ther. 2019;12:11359\u201369.","journal-title":"Onco Targets Ther"},{"key":"488_CR31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.18632\/oncotarget.1808","volume":"5","author":"A Lunardi","year":"2014","unstructured":"Lunardi A, Webster KA, Papa A, Padmani B, Clohessy JG, Bronson RT, et al. Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget. 2014;5:894\u2013900.","journal-title":"Oncotarget"},{"key":"488_CR32","first-page":"153","volume":"407","author":"M Aoki","year":"2017","unstructured":"Aoki M, Fujishita T. Oncogenic Roles of the PI3K\/AKT\/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153\u201389.","journal-title":"Curr Top Microbiol Immunol"},{"key":"488_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37116-5","volume":"14","author":"J Du","year":"2023","unstructured":"Du J, Liu Y, Wu X, Sun J, Shi J, Zhang H, et al. BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism. Nat Commun. 2023;14:1413.","journal-title":"Nat Commun"},{"key":"488_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118145","volume":"258","author":"B Zhang","year":"2020","unstructured":"Zhang B, Sun P, Shen CA, Liu X, Niu Y. Role and mechanism of PI3K\/AKT\/FoxO1\/PDX-1 signaling pathway in functional changes of pancreatic islets in rats after severe burns. Life Sci. 2020;258:118145.","journal-title":"Life Sci"},{"key":"488_CR35","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1038\/s41388-021-01742-4","volume":"40","author":"H Li","year":"2021","unstructured":"Li H, Han X, Yang S, Wang Y, Dong Y, Tang T. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53. Oncogene. 2021;40:2785\u2013802.","journal-title":"Oncogene"},{"key":"488_CR36","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-01-692129","volume":"127","author":"CT Baldari","year":"2016","unstructured":"Baldari CT. S1PR2 deficiency in DLBCL: a FOXy connection. Blood. 2016;127:1380\u20131.","journal-title":"Blood"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00488-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:05:53Z","timestamp":1732068353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00488-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":36,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00488-4","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments involving nude mice met the requirements and were approved by Xinhua Hospital of Shanghai Jiao Tong University School of Medicine (Animal experiment approval number: XHEC\u2013NSFC\u20132021-093, approval date: February 24, 2021). The study was approved by the Ethics Committee of Xinhua Hospital, Shanghai Jiaotong University School of Medicine. Informed consent was obtained from the patients for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have seen and approved the manuscript and consent publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}